Highest-materiality recent filing
Court invalidates two CINVANTI patents; Heron to appeal to Federal Circuit
U.S. District Court for Delaware ruled claims of Patents 12,115,255 and 12,290,520 invalid on June 1, 2026.
Heron Q1 net revenue $34.7M (-10.8% YoY); Acute Care up 32%; guidance reaffirmed
Total net revenue $34.7M vs $38.9M YoY; Acute Care franchise up 32% led by ZYNRELEF (+27%) and APONVIE (+50%).
Heron Therapeutics reports 2025 net revenue $154.9M, up 7.4%; issues 2026 guidance $173-183M
Full-year 2025 net revenue $154.9M (+7.4% YoY); Q4 net revenue $40.6M (-0.5% vs Q4 2024).
Heron Therapeutics preliminary Q4 2025 net revenue $40.5M; full-year $154.9M
Q4 2025 net revenue approximately $40.5M, driven by Acute Care franchise momentum.
Heron Q3 net revenue $38.2M, acute care +67% YoY, FY guidance reaffirmed
Q3 net revenue $38.2M (+16.5% YoY); YTD $114.3M.
Heron Therapeutics appoints Thomas Cusack to board under Rubric Capital agreement
Thomas Cusack appointed to Heron's board effective Oct 27, 2025; term expires at 2026 annual meeting.
Refinancing closed Aug 12: repurchased $125M of 2026 notes for cash, exchanged $25M for 16.67M shares; issued $35M notes due 2031 at $33.25M.
Q2 net revenue $37.2M (+3.3% YoY); year-to-date $76.1M (+7.7%); Acute Care revenue up 55.5% YoY.
Settlement resolves patent litigations in U.S. District Court for Delaware initiated in Sep 2023 and Jan 2024.
Net revenue of $38.9M, up 12.2% YoY; acute care franchise up 89.4% driven by ZYNRELEF (+60.4%).
Heron Q4 net income $3.6M; FY2024 rev $144.2M (+14%); guides 2025 rev $153-163M
Q4 2024 GAAP net income of $3.6M; full-year 2024 adjusted EBITDA of $8.6M.
Heron wins patent lawsuit against Fresenius Kabi over CINVANTI; generic blocked until 2035
Court ruled Heron's U.S. Patent Nos. 9,561,229 and 9,974,794 valid and infringed by Fresenius Kabi's proposed generic CINVANTI.
Q3 acute care franchise net product sales $7.4M (+57% YoY); oncology franchise $25.4M (-5% YoY).
Heron Therapeutics Q2 net product sales $36.0M; narrows 2024 guidance
Q2 net product sales $36.0M, up from $31.8M YoY; acute care franchise $6.8M, oncology $29.2M.
FDA acknowledged receipt of Prior Approval Supplement for ZYNRELEF Vial Access Needle (bupivacaine/meloxicam); PDUFA goal date September 23, 2024.
Heron shareholders approve increase in authorized shares to 400M and equity plan share expansion
Authorized common stock increased by 175M shares from 225M to 400M; effective June 13, 2024.
Heron Q1 2024 net product sales $34.7M (+17% YoY); net loss per share improves to $(0.02)
Net product sales $34.7M vs $29.6M YoY; net loss per share $(0.02) vs $(0.27).
Full-year 2023 oncology care franchise revenue $107.9M exceeded guidance; net product sales up 11% YoY.
On April 28, 2025, Heron Therapeutics, Inc. (the “ Company ”) announced that it appointed Mark Hensley as Chief Operating Officer, effective April 28, 2025
On November 4, 2024, the Board of Directors (the "Board") of Heron Therapeutics, Inc. (the "Company") appointed Michael Kaseta to the Board to serve for a term expiring at the Company’s 2025 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier death, resignation or removal.
On March 18, 2024, Ira Duarte was designated as Heron Therapeutics, Inc.’s principal accounting officer, replacing Lisa Peraza, the Company’s current Chief Accounting Officer and principal accounting officer, effective March 29, 2024 (the “Effective Date”).
Ms. Peraza will continue to serve in her current position until her employment with the Company ends on the Effective Date.
Max materiality 0.90 · Median 0.60 · Most common event earnings